Journal of Crohn's & colitis
Cure8 research brief
Why This Matters
Fatty liver is common in people with IBD and can signal fibrosis or cardiometabolic risk that affects long-term health. This review gives practical steps clinicians can use to decide who to test and how to follow up.
It clarifies that normal liver enzymes don’t rule out steatosis or fibrosis, and that imaging-based stiffness measures (transient elastography) are more informative for fibrosis than enzymes alone.
Who Should Pay Attention
Gastroenterologists and hepatologists managing adults with IBD; adult patients with IBD concerned about liver disease or metabolic risk; clinicians making medication choices for patients with IBD and liver abnormalities.
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This narrative review summarizes practical, evidence-based guidance on hepatic steatosis in adults with IBD.
It emphasizes that steatosis is common (affecting roughly one-quarter to one-third of patients by cohort and meta-analysis estimates), that identifying fibrosis and cardiometabolic risk is the clinical priority, and that screening should be risk-based rather than universal.
The review notes limitations of aminotransferases for excluding disease, suggests Fibrosis-4 index (FIB-4) as a pragmatic initial triage tool with IBD-specific caveats, and recommends transient elastography for secondary or combined fibrosis assessment.
It advises hepatology referral for elevated liver stiffness, persistent or cholestatic abnormalities, portal-hypertension features, suspected other liver disease, discordant tests, or significant hepatic dysfunction, and states steatosis alone should not dictate IBD drug selection.
Keep In Mind
This article is a narrative review (evidence synthesis) and the structured content depth is the source abstract. Recommendations are based on cohort studies, meta-analyses, and expert interpretation rather than a single randomized trial. Specific management should be individualized and discussed with a clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Crohn's & colitis
AuthorsGisbert JP, Lucendo AJ, Chaparro M
Study typeIm, review, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Transient Elastography for Liver Fibrosis and Steatosis in Inflammatory Bowel Disease: Current Evidence, Clinical Implications, and Future Directions
FibroScan detects liver fibrosis and steatosis that are common and sometimes under-recognized in people with IBD; identifying liver disease earlier could change monitoring or referral decisions, especially for patients...
Gastrointestinal manifestations of common variable immunodeficiency: what a gastroenterologist needs to be aware of.
CVID can cause GI problems that closely mimic Crohn’s disease, ulcerative colitis, or celiac disease and may change diagnostic and treatment choices. Gastroenterologists need to consider CVID when IBD presentations are...
Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission.
Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.